In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo
The clinical study was approved by an independent ethics committee (rztekammer Nordrhein, Dsseldorf, Germany
On a biological level, GHK-Cu stimulates cell repair processes, supports the synthesis of collagen and elastin, and activates growth factors responsible for the renewal of skin, blood vessels, and connective tissues
Lawsuits point to evidence that drugmakers were aware of more long-term risks than they disclosed, continuing to market GLP-1 drugs as safe for widespread use
10.1038/s42255-020-00327-x 50 GromadaJ.FranklinI.WollheimC
Pour modifier vos prfrences par la suite, cliquez sur le lien 'Grer mes cookies' situ dans le pied de page.